By Tom Ulrich
Oncology
Philips Healthcare teams with P-Cure on proton therapy
VuComp wins FDA clearance for breast density measurement tool
VuComp said it won 510(k) clearance from the FDA for its M-Vu breast density tool, which provides automated assessment of breast density from a digital mammogram.
The M-Vu uses advanced computer vision algorithms to evaluate the appearance of structures and textures in the breast to differentiate between fatty and dense regions. It then calculates a percentage of breast area that is dense, translating it to 1 of 4 density categories corresponding to the BI-RADS standard.
Philips wins 510(k) clearance for breast density measurement tool
ViewRay aims global with new $30M in funding for MRI-guided radiation therapy
Ohio-based ViewRay Inc. is looked to widen its global commercial reach with new funds raised from both new and existing investors.
ViewRay touted $30 million in new funding that the privately held company plans to use to market its ViewRay MRI-guided radiation therapy system around the world.
Breast cancer: Seno Medical hits 100th patient in Imagio pivotal trial
Seno Medical Instruments touted the 100th patient enrolled in a pivotal clinical study of the company’s Imagio system, an opto-acoustic breast imaging platform designed to help prevent unnecessary biopsies.
Canada’s Verisante raises $1.1M for cancer detection
Germany’s BioCer lands E.U. win for mastectomy bra, U.S. win for hernia mesh
German medical device maker BioCer this week touted regulatory wins in the U.S. and in the U.K. for devices in its TiO2Mesh line, including for its mastectomy bra and hernia repair mesh.
Surefire Medical lands $18M Series B round
Surefire Medical said it brought in $18.2 million in a Series B funding round it plans to use to further development of its infusion device for liver cancer.
The Westminster, Colo.-based medical device company said new backer Super Angel investors joined existing investors MCG Partners, Partisan Management Group and High Country Ventures in the round.
Intuitive Surgical gains points on lung cancer study
Troubled Delcath announces $7.5M offering, drops 23%
New York’s Delcath Systems (NSDQ:DCTH) is looking to raise about $7.5 million through sales of common stock, planning on using the funds for working capital, commercialization efforts, clinical trials and other "general corporate purposes."